Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.0150) per share and revenue of $20.1640 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.
Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $32.36 million for the quarter, compared to the consensus estimate of $30.75 million. Xtant Medical had a return on equity of 10.27% and a net margin of 3.71%.
Xtant Medical Price Performance
NYSEAMERICAN:XTNT traded up $0.03 during trading hours on Tuesday, reaching $0.59. 77,672 shares of the company were exchanged, compared to its average volume of 157,284. The company has a market capitalization of $82.18 million, a P/E ratio of 19.56 and a beta of -0.11. Xtant Medical has a 1-year low of $0.44 and a 1-year high of $0.95. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.65 and a quick ratio of 1.63. The business has a 50 day moving average of $0.55 and a 200 day moving average of $0.64.
Institutional Investors Weigh In On Xtant Medical
Wall Street Analysts Forecast Growth
XTNT has been the topic of a number of analyst reports. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a research report on Wednesday, March 18th. BTIG Research reduced their price target on Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $1.00.
View Our Latest Report on Xtant Medical
Xtant Medical Company Profile
Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.
The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.
Read More
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
